Zhejiang Taimei Med Tech Co (2576) Fair Value & Analysis
Healthcare · HK · Market cap HK$3.8B
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$1.71 to HK$1.70 (−0.6%) since Jul 7, 2026. Share price −7.1% over the past month.
A solid business, but screening 70% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$2.13). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (HK$1.12 to HK$2.13) leaves room in how you read the outcome.
Price vs Fair Value (22 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
22‑month range HK$3.10 – HK$9.20 · fair‑value band HK$1.12 – HK$2.13 · the HK$5.67 price screens above the HK$1.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Zhejiang Taimei Med Tech Co (2576) currently trades at HK$5.67, while our model-based Fair Value estimate is HK$1.70, implying the stock looks roughly 70.0% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Zhejiang Taimei Med Tech Co generated revenue of HK$513M at a net margin of -8.4%. Revenue declined 3.6% year over year. It earns a return on equity of -4.2%. The balance sheet holds a net cash position of HK$564M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$1.12 (bear case) to HK$2.13 (bull case); at HK$5.67, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 71% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -70%, 2576 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 2576 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhejiang Taimei Medical Technology Co., Ltd. provides digital solutions for life sciences research, development, and commercialization in Mainland China and internationally.
Full company description
Zhejiang Taimei Medical Technology Co., Ltd. provides digital solutions for life sciences research, development, and commercialization in Mainland China and internationally. The company offers Wiz.AI, an AI platform for clinical trials; TrialOS pharmaceutical R&D collaboration platform; PharmaOS, a pharmaceutical digital marketing platform; and the enterprise-medical academic interaction platform. It also provides pharmaceutical R&D solutions comprising eCollect, eBalance, eCooperate, eArchives, eImage medical imaging evaluation system, eSMS site management system, Paylite financial management system, and eCollege training management system; TrialPartner digital SMO services, IRC independent review center solutions, and eSAE clinical trial safety information management system; eSitePro clinical trial management platform, eTrialPro research ward management system, GCP-X intelligent clinical trial platform, IIT-EDC research data collection system, eScreening subject information management system, eMonitoring intelligent remote monitoring system, and IDS investigational drug services; and IDCT intelligent decentralized clinical trial. In addition, the company offers eSafety pharmacovigilance compliance management system; eSAE clinical trial safety information management system; ONECEM omni-channel marketing platform, such as ONECEM-SFE sales operation system, ONECEM-SCRM intelligent marketing system, and ONECEM-event+engagement system; and ONEInsight marketing data platform, including boundless corporate medical interaction platform. Further, it provides research and development support; technical, clinical operation, data management, statistical analysis, and management services; independent image evaluation services; and pharmaceutical marketing and institution digitalization solutions. The company was formerly known as Jiaxing Taimei Medical Technology Co., Ltd. Zhejiang Taimei Medical Technology Co., Ltd.was founded in 2013 and is headquartered in Jiaxing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Taimei Med Tech Co reported revenue of HK$499M in FY2025 versus HK$466M in FY2021, a compound +1.7%/yr. Reported net income was −HK$41.7M in FY2025.
2576 screens 70% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $58.48 | $17.18 | -71% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare Zhejiang Taimei Med Tech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhejiang Taimei Med Tech Co (2576) overvalued or undervalued?
What is the fair value of 2576?
What is the quality score of 2576?
What is the revenue of Zhejiang Taimei Med Tech Co (2576)?
What is the net profit margin of 2576?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhejiang Taimei Med Tech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.